Floatz logo

Epirubicin

Carcinoma, Intraductal, Noninfiltrating

Laura EssermanEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Carcinoma, Intraductal, Noninfiltrating cohort.

Asset / SponsorPhaseRating
FAPi-46
Universität Münster
Phase 2CCC
Chloroquine
Inova Health Care Services
Phase 1/2CCC
Cyclophosphamide
Laura Esserman
Early Phase 1C
Mrna-2752
Laura Esserman
Early Phase 1C
Pembrolizumab
Laura Esserman
Early Phase 1C
IRON SUCROSE
Columbia University
Early Phase 1C

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →